Malte Peters, MD joined MorphoSys AG in 2017 as chief development officer and a member of the management board and will move into the role of chief research and development officer in March of 2020. Previously, he served as global head of clinical development of the biopharmaceuticals business unit of Sandoz International in Holzkirchen, Germany. Before joining Sandoz, Malte spent 12 years as a leader in Novartis Oncology, ultimately serving as VP, clinical and site head for Basel, East Hanover N.J. and Shanghai for the early clinical development group. Earlier in his career, he worked at Merck KGaA as director of cancer research and head of translational research and pharmacogenomics.

Malte received his medical degree from Freie Universität in Berlin, did a postdoctoral fellowship with Tak Wah Mak, PhD in Toronto, and has held teaching appointments in internal medicine and biochemistry at the University of Mainz.